NASDAQ$TOI
Oncology Institute Inc/The · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results with revenue increase driven by expansion and value-based approach.
The Oncology Institute (TOI) reported a strong first quarter in 2022 with a 13.5% increase in revenue compared to Q1 2021, reaching $55 million. The company also saw a rise in gross profit and net income, driven by new partnerships and cost management improvements.
- Revenue increased by 13.5% to $55 million compared to Q1 2021.
- Gross profit increased by 20.8% compared to Q1 2021.
- Initiated three new value-based partnerships, including one with MaxHealth.
- Net income for Q1 2022 was $19 million, increasing $20 million over the same quarter last year.
Headline financials
Revenue & EPS history
Oncology Institute · Revenue · Quarterly
$55.2M
Revenue by segment
Oncology Institute · $55.2M total across 3 segments · Q1 2022
- Patient Services$35.1M+18.3%63.6%
- Dispensary$18.7M+6.0%33.9%
- Clinical Trials & Other$1.43M+6.3%2.6%
Forward guidance
The Oncology Institute confirms its full year 2022 guidance with revenue expected between $270 million and $310 million.
Tailwinds
- Revenue between $270 million and $310 million, representing approximately 33% to 53% growth over 2021 revenue
- Gross Profit between $50 to $60 million
- Value-based lives between 1.75 million to 2.0 million lives, representing approximately 9% to 25% growth over year-end 2021 lives
- Interest expense in the range of $0.5 million and $1 million
- Depreciation and amortization in the range of $4 million and $6 million
Headwinds
- Adjusted EBITDA between $(20) to $(25) million
- Uncertainties regarding taxes
- Uncertainties regarding share-based compensation
- Our outlook assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented.
- The outlook does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of our acquisitions, dispositions or financings during 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+2.6%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+8.0%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+28.9%
Q3 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.8% | +5.8% | +27.9% | |
| Q4 2025 | +8.4% | +37.4% | +17.6% | |
| Q3 2025 | +28.9% | +6.2% | +22.7% | |
| Q1 2025 | +28.3% | +17.3% | +4.2% | |
| Q4 2024 | +24.5% | +14.5% | +189.2% | |
| Q3 2024 | -23.4% | -43.8% | -5.1% | |
| Q2 2024 | -20.4% | -11.1% | -26.9% | |
| Q1 2024 | +3.6% | -26.5% | -46.6% | |
| Q4 2023 | +8.9% | -7.7% | -32.0% | |
| Q3 2023 | +5.7% | +46.6% | -27.6% | |
| Q2 2023 | -10.1% | -13.3% | +28.3% | |
| Q1 2023 | +4.2% | -6.3% | +29.2% | |
| Q4 2022 | +1.9% | -5.8% | -30.6% | |
| Q3 2022 | -4.3% | -35.5% | -66.4% | |
| Q2 2022 | +0.6% | -1.2% | -9.6% | |
| Q1 2022 | -14.7% | -11.8% | -6.5% | |
| Q2 2021 | +10.3% | +31.4% | +48.1% | |
| Q4 2020 | +10.3% | +31.4% | +48.1% | |
| Q4 2021 | -14.6% | +18.5% | +26.5% | |
| Q3 2021 | +0.0% | +10.0% | -23.6% | |
| Q1 2021 | -0.2% | +1.0% | +0.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro